Literature DB >> 26088265

Irritable bowel syndrome: new and emerging treatments.

Magnus Halland1, Yuri A Saito2.   

Abstract

Irritable bowel syndrome is one of the most common gastrointestinal disorders in developed nations. It is characterized by abdominal pain, altered bowel habits, and bloating. Several non-pharmacological and pharmacological agents, which target the peripheral gastrointestinal system and central nervous system, are used to treat the syndrome. The individual and societal impact of investigating and managing the syndrome is substantial, and despite newer treatments, many patients have unmet needs. Intense research at many international sites has improved the understanding of pathophysiology of the syndrome, but developing treatments that are effective, safe, and that have tolerable side effects remains a challenge. This review briefly summarizes the currently available treatments for irritable bowel syndrome then focuses on newer non-pharmacological and pharmacological therapies and recent evidence for older treatments. Recent guidelines on the treatment of irritable bowel syndrome are also discussed. © BMJ Publishing Group Ltd 2015.

Entities:  

Mesh:

Year:  2015        PMID: 26088265     DOI: 10.1136/bmj.h1622

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  13 in total

1.  Understanding and Managing IBS and CIC in the Primary Care Setting.

Authors:  Brooks D Cash
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

Review 2.  Novel perspectives on therapeutic modulation of the gut microbiota.

Authors:  Justin L McCarville; Alberto Caminero; Elena F Verdu
Journal:  Therap Adv Gastroenterol       Date:  2016-04-04       Impact factor: 4.409

3.  Irritable Bowel Syndrome.

Authors:  Kristen Ronn Weaver; Gail DʼEramo Melkus; Wendy A Henderson
Journal:  Am J Nurs       Date:  2017-06       Impact factor: 2.220

4.  SYMPOSIUM REPORT: An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice: A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting October 16, 2016 • Las Vegas, Nevada.

Authors:  William D Chey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-02

5.  Shuganyin decoction improves the intestinal barrier function in a rat model of irritable bowel syndrome induced by water-avoidance stress.

Authors:  Lu Lu; Liang Yan; Jianye Yuan; Qing Ye; Jiang Lin
Journal:  Chin Med       Date:  2018-02-01       Impact factor: 5.455

6.  Sildenafil normalizes bowel transit in preclinical models of constipation.

Authors:  Sarah K Sharman; Bianca N Islam; Yali Hou; Margaux Usry; Allison Bridges; Nagendra Singh; Subbaramiah Sridhar; Satish Rao; Darren D Browning
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

7.  Biofeedback for treatment of irritable bowel syndrome.

Authors:  Joshua Z Goldenberg; Matthew Brignall; Michelle Hamilton; Jennifer Beardsley; Richard D Batson; Jason Hawrelak; Brad Lichtenstein; Bradley C Johnston
Journal:  Cochrane Database Syst Rev       Date:  2019-11-12

Review 8.  Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.

Authors:  Aleksandra Sobolewska-Włodarczyk; Marcin Włodarczyk; Martin Storr; Jakub Fichna
Journal:  Ther Clin Risk Manag       Date:  2016-05-13       Impact factor: 2.423

9.  Altered Intestinal Microbiota with Increased Abundance of Prevotella Is Associated with High Risk of Diarrhea-Predominant Irritable Bowel Syndrome.

Authors:  Tingting Su; Rongbei Liu; Allen Lee; Yanqin Long; Lijun Du; Sanchuan Lai; Xueqin Chen; Lan Wang; Jianmin Si; Chung Owyang; Shujie Chen
Journal:  Gastroenterol Res Pract       Date:  2018-06-05       Impact factor: 2.260

10.  Microbial evolution and ecological opportunity in the gut environment.

Authors:  Pauline D Scanlan
Journal:  Proc Biol Sci       Date:  2019-11-20       Impact factor: 5.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.